DREAMM-2 safety summary
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
has been added to your basket
59
For Great Britain (GB) healthcare professionals only. Not available in Northern Ireland (NI).
BLENREP has a conditional marketing authorisation.
BLENREP has a generally well tolerated and manageable safety profile1
BLENREP is only available via the private market.
In the final analysis (40 months follow-up) of the DREAMM-2 trial, BLENREP (administered as 2.5 mg/kg every 3 weeks) delivered an overall response rate of 32% (n=31/97; 95% CI 21.7-43.6) in triple-refractory patients with multiple myeloma. 58% (n=18) of responding patients achieved a ≥VGPR. Responses to BLENREP were fast, deep and durable.2
of affected patients (n=49/67) had recovered from their first keratopathy event by the final analysis data cut off2‡
of responses (n=14/16) were sustained or deepened, despite prolonged dose delays (from post-hoc analysis in 13 month follow up).3
BLENREP, 2.5 mg/kg (n=95) |
|||
---|---|---|---|
Keratopathy |
Blurred vision | BCVA reduced to 20/50 or worse | |
Incidence, % (n) | 71% (67) | 25% (24) | 19% (18) |
Median time to resolution of first event, days (range) | 120.0* (8–858) | 43.0 (6–895) | 21.5 † (7-64) |
Recovered as of last assessment, % (n) | 73% (49/67) | 79% (19/24) | 89% (44/46) |
Clinical outcomes in a post-hoc analysis of patients who had prolonged dose delays (in which ≥3 treatment cycles were missed) in the 13-month follow up, after initially responding to BLENREP 2.5mg/kg (n=16/31)*3
With BLENREP, there was no change in overall patient-reported Global Health Status/QoL, Physical Functioning, or Role Functioning domain scores of the EORTC-QLQ-C30 at the final readout vs. baseline. This included patients with a minimal meaningful withinpatient reduction in vision-related function by Ocular Surface Disease Index (OSDI).3
BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.1
Prescribing information can be found at the top of this webpage, or here.
Abbreviations
AE, adverse event; BCVA, best corrected visual acuity; BL, baseline; CI, confidence interval; DREAMM-2, DRiving Excellence in Approaches to Multiple Myeloma 2; EORTC-QLQ-C30, European Organisation for Research and Treatment of cancer quality of life questionnaire; GB, Great Britain; NI, Northern Ireland ORR, Overall Response Rate; OSDI, Ocular Surface Disease Index; PS, performance status; Q3W, every 3 weeks; QoL, quality of life; R-ISS, Revised International Staging System; SAE, Severe adverse event; SmPC, Summary of Product Characteristics; VGPR, Very good partial response;
References
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or email us on UKSafety@gsk.com.
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
February 2024 | PM-GB-BLM-WCNT-220004 (V5.0)